Studies of the biochemical pharmacology of the fermentation-derived antitumor agent, (αS, 5S) -α-amino-3-chloro-4, 5-dihydro-5-isoxazoleacetic acid (at-125)

Hanka, 1967, In vitro screen for antimetabolites, Vol. 3, 351 Hanka, 1978, In vitro methods used in detection and quantitation of antitumor drugs produced by microbial fermentations, Lloydia, 41, 85 Hanka, 1966, Microbiological production of 5azacytidine, I. Production and biological activity, Antimicrob. Agents Chemotherap., 619 Von Hoff, 1976, 5-Azacytidine, a new anticancer drug with effectiveness in acute myelogenous leukemia, Ann. Internal Med., 85, 237, 10.7326/0003-4819-85-2-237 Hanka, 1973, U-42, 126. a new antimetabolite antibiotic: Production, biological activity, and taxonomy of the producing microorganism, Antimicrob. Agents Chemother., 3, 425, 10.1128/AAC.3.3.425 Hanka, 1973, A new antitumor antimetabolite, (αS, 5S)-α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): Antimicrobial reversal studies and preliminary evaluation against L1210 mouse leukemia in vivo, Cancer Chemother. Repts., 57, 141 Martin, 1973, The isolation, structure, and absolute configuration of U-42, 126 a novel antitumor antibiotic, Tetrahedron Lett., 27, 2549, 10.1016/S0040-4039(01)96202-1 Hanka, 1975, Improved methods for production, isolation and assay of two new chloroisoxazoline amino acid antitumor antimetabolites: U-42, 126 and U-43, 795, Antimicrob. Agents Chemother., 7, 807, 10.1128/AAC.7.6.807 Martin, 1975, The isolation structure, and absolute configuration of U-43, 795, a new antitimor agent, J. Antibiot., 28, 91, 10.7164/antibiotics.28.91 Martin, 1974, A new antitumor agent, (αS, 4S, 5R)-α-amino-3-chloro-4-hydroxy-4,5-dihydro-5-isoxazoleacetic acid (NSC-176324): Preliminary evaluation against L1210 mouse leukemia in vivo, Cancer Chemother. Rep., 58, 935 Houchens, 1978, Therapy of mouse tumors and human tumor xenografts by the antitumor antibiotic AT-125 (NSC-163501), 19, 40 Kelly, 1978, Total synthesis of AT-125, an unusual antitumor, antibiotic amino acid Smith, 1959, An improved tissue culture assay. I. Methodology and cytotoxicity of antitumor agents, Cancer Res., 19, 843 Bhuyan, 1973, Cell-kill kinetics of several S-phase-specific drugs, Cancer Res., 33, 888 Neil, 1973, The effect of dose interval on the survival of L1210 leukemic mice treated with DNA synthesis inhibitors, Cancer Res., 33, 895 Neil, 1976, Combination chemotherapy of L1210 leukemia with 1-α-D-arabinofuranosylcytosine and 5-azacytidine, Cancer Res., 36, 1114 Geran, 1972, Protocols for screening chemical agents and natural products against animal tumors and other biological systems, Cancer Chemother, Repts., 3, 1 Jayaram, 1975, L-[αS, 5S]-α-amino-3-chloro-4, 5-dihydro-5-isoxazoleacetic acid (NSC-163501): A new amino acid antibiotic with the properties of an antagonist of l-glutamine, Cancer Chemother. Repts., 59, 481 Cooney, 1974, Inhibition of L-asparagine synthetase by a new amino acid antibiotic with antitumor activity; L-(αS, 5S)-α-amino-3-chloro-4, 5-dihydro-5-isoxazoleacetic acid (NSC-163501), Cancer Chemother. Repts., 58, 793 Bloch, 1974, Prevention, by testosterone, of the intestinal toxicity caused by the antitumor agent 3-deazauridine, Cancer Res., 34, 1299 McPartland, 1974, Cytidine 5′-triphosphate synthetase as a target for inhibition by the antitumor agent 3-deazauridine, Cancer Res., 34, 3111 Neil, 1979, Biochemical and pharmacological effects of the fermentation-derived antitumor agent, (αS, 5S)-α-amino-3-chrolo-4, 5-dihydro-5-isoxazoleacetic acid (AT-125), Cancer Res., 39, 852 Weber, 1977, Enzymatic markers of neoplastic transformation and regulation of purine and pyrimidine metabolism, Advances in Enzyme Regulation, 15, 53, 10.1016/0065-2571(77)90009-7